Manufacturers submit Emergency Use Authorisation Application to FDA for Zyesami™ (aviptadil-acetate) to treat critical COVID-19 in patients with respiratory failure

The application for this synthetic form of Vasoactive Intestinal Polypeptide was supported by data from a study which found statistically significant improvements in mortality and absence of respiratory failure at 60 days vs placebo, as well as shorter median hospital stays.

Source:

Biospace Inc.